Pharm Flashcards
ADHD stimulants
Amphetamine salts- increase release of dopamine and norepinephrine from synaptic terminal, shorter acting
Methylphenidate- less potent, less side effects, increase dopamine release from presynaptic terminal, shorter onset, longer acting
Stimulant side effects
Decreased appetite, psychosis (dose related risk), abuse/dependence, tremor, nausea, arrhythmia and sudden cardiac death, exacerbation of tics, hypertension, insomnia
ADHD non-stimulants
Lesser extent of blocking than stimulants
Requires time to have effect- like anti-depressants
Atomoxetine- increases NE only by blocking reuptake
Buproprion- blocks reuptake of DA and NE. Lowers seizure threshold, contraindicated in eating disorder patients, tremor, insomnia, side effects related to formulation (extended release has less SE)
Guanfacine/clonidine- alpha 2 agonist acts at autoreceptors to decrease calcium influx and subsequent decrease in NE/DA globally to act on the hyperactive/hyperkinetic symptoms. Increase NTs in prefrontal cortex with other meds.
Tic disorder treatments
Alpha 2 agonists
If this doesn’t work, try a D2 antagonist (antipsychotic)
But usually non pharmacological approaches
Glaucoma agent categories and MOA
Beta-adrenergic antagonists- decreased production
Cholinergic agonist (miotics)- increased outflow
Adrenergic agonist- alpha 2- decreased production at first and then later increased outflow
Carbonic anhydrase inhibitors- decreased production
Prostaglandins- increased outflow
Hyperosmotics
Cholinergic Agents for glaucoma
MOA
Pilocarpine- directly acting agonist
Indirect acting agonist- echothiophate binds AChE
Increases aqueous outflow through the trabecular meshwork by longitudinal ciliary muscle contraction (pupillary constriction and accommodation)
Beta-adrenergic blockers
-olol
These receptors usually cause pupillary dilation and make more aqueous humor
Reduced aqueous humor production by interrupting binding beta adrenergic receptors
SEs: fatigue, bradycardia, asthma
Alpha 2 Adrenergic agonists
Brimonidine, apraclonidine
Decreased aqueous production and increase uveoscleral outflow
Non-specific alpha agonists
Rarely used- epinephrine, pro-drug epi (dipivefrin)
Carbonic anhydrase inhibitors
-zolamide
Oral or topical
Aqueous suppression by inhibiting CA enzyme at the nonpigmented epithelium
Prostaglandin analogues
-prost
Increased uveoscleral aqueous outflow
Side effects are minimal
Most commonly used first line agent
Balanced anesthesia
A specific drug for each goal, limiting the side effects of each
Unconsciousness- propofol
Amnesia- benzodiazepine
Analgesia- fentanyl
Inhibition of reflexes- glycopyrrolate (anti-cholinergic)
Skeletal muscle relaxation- vecuronium (anti-cholinergic)
Premedication anesthesia
Allay fear and anxiety, create amnesia, reduce pain, reduce dose of subsequent anesthetics
Common choices: midazolam (benzo), morphine or fentanyl
Benzodiazepines- short acting and long acting
Oxazepam
Lorazepam
Midazolam- has an active metabolite (alpha-hydroxymidazolam)
Diazepam (Valium)- active metabolites: oxazepam, N-desmeyhyldiazepam, N-methyloxazepam
Elimination of benzosdiazepines and SEs
Redistribution is most important, conjugated to glucuronides, eliminated by the kidney
Elimination is slowed in elderly and critically ill (sepsis)
Long half life, but their effect doesn’t last the duration of their half life because they are redistributed out of the NS
Dissociative effect- can cause problems in those with baseline dementia and confusion